# ROSETTA Lung-107: HCP commentary report

> 16 verified statements (2 from clinicians verified by NPI or staff page) from 5 commentary sources · 4 findings · updated Oct 28, 2026

## Report

- Trial: A Phase II, Multisite, Open-label Trial of Pumitamig (BNT327) in Combination With Standard-of-care Chemotherapy in First-line and Second-line Non-small Cell Lung Cancer (NSCLC)
- NCT ID: NCT06841055
- Registry: https://clinicaltrials.gov/study/NCT06841055
- Sponsor: BioNTech SE
- Phase: Phase 2
- Status: Recruiting
- Drugs: docetaxel
- Indications: Non-small cell lung cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-10-28
- Last checked: 2026-10-28
- Release hash: a4bda293047aa55a658c48ddb3008069b9a3e3888436949881cea4aa2086570b

## Counts

- HCP commentary sources screened: 14
- Sources cited by verified statements: 5
- Verified statements: 16
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 2
- Findings: 4
- People found in screened sources: 2
- People identity-verified: 2
- Voices cited: 2
- Organisational or shared accounts (not counted as people): 2

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

ROSETTA Lung-107 examines whether pumitamig with chemotherapy can improve outcomes in NSCLC, with discussion focused on docetaxel after chemoimmunotherapy. In the sources reviewed for this edition, favorable clinical reactions coexist with an unresolved added-benefit question. A medical oncologist expresses safety reassurance and relayed investigator remarks welcome activity; X-thread discussions scrutinize comparative benefit. How subgroup findings should guide treatment selection, and how alternative docetaxel combinations compare, remain open.

## Open Medical Affairs question

Would a randomized comparison show that adding pumitamig improves outcomes over contemporary second-line treatment?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. An encouraging signal leaves the added-benefit question unanswered
- F2. Reassurance about safety coexists with high-grade toxicity and differing bleeding summaries
- F3. Activity across subgroups supports further study, not a selection rule or proven mechanism
- F4. Strategy-level enthusiasm does not rank alternative docetaxel combinations

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 5 | 2 | 2 | 2 | none recorded | 2 |
| F2 | 5 | 3 | 3 | 3 | none recorded | 2 |
| F3 | 4 | 3 | 3 | 3 | none recorded | 2 |
| F4 | 2 | 2 | 2 | 2 | none recorded | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 1 | 1 | 0 | 1 | 2 | 5 | 0 | 2 posts and articles | yes |
| F2 | 3 | 0 | 0 | 1 | 1 | 5 | 0 | 3 posts and articles | yes |
| F3 | 1 | 0 | 0 | 0 | 3 | 4 | 0 | 3 posts and articles | yes |
| F4 | 1 | 0 | 0 | 1 | 0 | 2 | 0 | 2 posts and articles | no |

### Trial dimensions

- Primary endpoint: Part 1 - Occurrence of dose limiting toxicities (DLTs): F2 (2 shared claims)
- Primary endpoint: Part 1 and Part 2 - Occurrence of pumitamig treatment emergent adverse events, treatment-related adverse events, treatment emergent serious adverse events, treatment-related serious adverse events, and adverse events of special interest: F2 (5 shared claims)
- Primary endpoint: Part 1 and Part 2 - Occurrence of dose interruption, dose reduction, and/or participant discontinuation due to adverse events: F2 (1 shared claims)
- Primary endpoint: Part 1 and Part 2 - Objective response rate: F1 (2 shared claims), F3 (4 shared claims), F4 (1 shared claims)
- Secondary endpoints: F1 (3 shared claims), F3 (3 shared claims), F4 (1 shared claims)
- Population and setting: F1 (1 shared claims), F2 (1 shared claims), F3 (4 shared claims), F4 (2 shared claims)
- The comparison: F1 (3 shared claims), F4 (1 shared claims)
- Safety and tolerability: F2 (5 shared claims)
- Design and conduct: F1 (4 shared claims), F4 (1 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 4 | Titles free |
| Detailed analysis | 5 sections | Paid |
| Verified statements with short source quotes and links | 16 | Paid |
| Trial aspects mapped | 12 | Free |
| Sources with links | 5 | Counts free |
| Speaker attribution for cited voices | 2 | Paid |

## Trial aspects

12 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Part 1 - Occurrence of dose limiting toxicities (DLTs) | discussed | 2 | 2 |
| Primary endpoint: Part 1 and Part 2 - Occurrence of pumitamig treatment emergent adverse events, treatment-related adverse events, treatment emergent serious adverse events, treatment-related serious adverse events, and adverse events of special interest | discussed | 5 | 3 |
| Primary endpoint: Part 1 and Part 2 - Occurrence of dose interruption, dose reduction, and/or participant discontinuation due to adverse events | discussed | 1 | 1 |
| Primary endpoint: Part 1 and Part 2 - Objective response rate | discussed | 7 | 4 |
| Secondary endpoints | discussed | 7 | 4 |
| Population and setting | discussed | 8 | 5 |
| The comparison | discussed | 4 | 3 |
| Safety and tolerability | discussed | 5 | 3 |
| Design and conduct | discussed | 5 | 3 |
| PD-L1 and histology: breadth of activity versus differential benefit | discussed | 4 | 3 |
| Potential immune re-engagement after chemoimmunotherapy | discussed | 1 | 1 |
| Alternative immune–angiogenic combinations | discussed | 1 | 1 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 13 | 5 |
| Bluesky threads | 1 | 0 |

- Screened window: 2026-09-26 to 2026-10-25
- Cited window: 2026-10-25 to 2026-10-25
- Retrieved: 2026-10-28

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase II, Multisite, Open-label Trial of Pumitamig (BNT327) in Combination With Standard-of-care Chemotherapy in First-line and Second-line Non-small Cell Lung Cancer (NSCLC)
- Registry: NCT06841055 (https://clinicaltrials.gov/study/NCT06841055)
- Study IDs: BNT327-07 · 2024-518279-80-00
- Sponsor: BioNTech SE
- Collaborators: BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
- Design: Phase 2 · interventional, non randomized, sequential, phase2
- Status: Recruiting
- Enrollment: 60 (estimated)
- Start: 2025-03-03 (actual)
- Primary completion: 2028-10 (estimated)
- Primary endpoint: Part 1 - Occurrence of dose limiting toxicities (DLTs) (Up to 21 days after first dose of investigational medicinal product (IMP))
- Primary endpoint: Part 1 and Part 2 - Occurrence of pumitamig treatment emergent adverse events, treatment-related adverse events, treatment emergent serious adverse events, treatment-related serious adverse events, and adverse events of special interest (From initiation of the first dose of IMP to the 90-day Follow-Up visit)
- Primary endpoint: Part 1 and Part 2 - Occurrence of dose interruption, dose reduction, and/or participant discontinuation due to adverse events (From initiation of the first dose of IMP until the 90-day Safety Follow-up visit)
- Primary endpoint: Part 1 and Part 2 - Objective response rate (Up to approximately 2 years)
- Intervention: Pumitamig (drug)
- Intervention: Docetaxel (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 8 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits apply, so some matching discussion may be missing.
- The sources reviewed for this edition are not a representative survey of HCPs. Presentation summaries, relayed statements and account commentary should not be counted as independent clinician endorsements.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- No results publication for NCT06841055 was found, no protocol was listed on ClinicalTrials.gov, and no exact pumitamig regulatory label was identified. The report describes commentary, not a complete assessment of the trial or prescribing information.
- The safety summaries differ on bleeding severity, reporting grade 1 versus grades 1 or 2; the available statements do not explain the difference.
- Historical and cross-study comparisons, descriptive subgroup results and a relayed mechanistic hypothesis do not establish comparative efficacy, comparative safety or a treatment-selection rule.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-28: current edition, corrected 2026-10-28
  - Correction 2026-10-28: The trial is named ROSETTA Lung-107, as its sources and the report name it (was BNT327-07)
  - Correction 2026-10-28: Corrected to match the delivered report: the report description.

Last checked for new commentary 2026-10-28. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (16 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (2 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/rosetta-lung-107-nct06841055
- Agents: POST https://www.erudio.com/api/orders with {"report": "rosetta-lung-107-nct06841055", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=rosetta-lung-107-06841055

## Cite

Erudio Health. ROSETTA Lung-107 (NCT06841055): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 28, 2026. https://www.erudio.com/reports/rosetta-lung-107-nct06841055

## Machine access

- JSON: https://www.erudio.com/reports/rosetta-lung-107-nct06841055.json
- Markdown: https://www.erudio.com/reports/rosetta-lung-107-nct06841055.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "rosetta-lung-107-06841055"}`